As part of our series focussing on medicines available in Australia, we have added a product review of the use of sucroferric oxyhydroxide in the management of hyperphosphataemia in chronic kidney disease patients undergoing peritoneal dialysis.
This review discusses current management of hyperphosphataemia, indications and dosage of sucroferric oxyhydroxide, contraindications and a series of clinical studies featuring its use. It provides commentary from Dr Hilton Gock, staff specialist in Nephrology and General Medicine at St Vincent’s Hospital Melbourne.
Please login below to download this issue (PDF)